Literature DB >> 29861319

Circulating Galectin-3 is Associated With Left Atrial Appendage Remodelling and Thrombus Formation in Patients With Atrial Fibrillation.

Zhengde Tang1, Lefeng Zeng1, Yanjun Lin1, Zhihua Han1, Jun Gu1, Changqian Wang2, Huili Zhang3.   

Abstract

BACKGROUND: Left atrial appendage (LAA) is gaining increasing attention in patients with atrial fibrillation (AF) in the context of cardioembolic stroke. Galectin-3 (Gal-3) is a mediator of profibrotic pathways and is associated with an increased incidence of heart failure. However, the role of Gal-3 in LAA remodelling and thrombus formation in AF has not been evaluated.
METHODS: This prospective study included 153 consecutive patients with paroxysmal (n=58), persistent (n=55) or permanent (n=40) nonvalvular AF. The serum level of Gal-3 was measured by enzyme-linked immunosorbent assay. The morphology and function of LAA were determined by transoesophageal echocardiography.
RESULTS: Left atrial appendage thrombus was observed in 22 patients (2 in paroxysmal AF, 11 in persistent AF and 9 in permanent AF). Significant differences among patients with different types of AF were found in terms of LAA morphology (orifice diameter and depth) and function (flow velocity and tissue Doppler contracting velocity) as well as serum levels of Gal-3. Furthermore, patients with persistent or permanent AF had higher levels of Gal-3. High Gal-3 level was closely related to LAA flow velocity and occurrence of LAA thrombus. Multivariate logistic regression analysis revealed that Gal-3 was an independent determinant of LAA thrombus in patients with AF. Receiver operating characteristic (ROC) curves related to LAA thrombus formation established a cut-off point for Gal-3 >18.95ng/ml.
CONCLUSIONS: Cardiac rhythm disturbances caused by AF may lead to morphologic and functional remodelling of LAA. The serum level of Gal-3 was significantly correlated with LAA remodelling in patients with AF. High levels of Gal-3 were also a predicator for LAA thrombus formation.
Copyright © 2018 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; Galectin-3; Left atrial appendage; Transoesophageal echocardiography

Mesh:

Substances:

Year:  2018        PMID: 29861319     DOI: 10.1016/j.hlc.2018.05.094

Source DB:  PubMed          Journal:  Heart Lung Circ        ISSN: 1443-9506            Impact factor:   2.975


  6 in total

1.  Circulating Galectin-3 and Atrial Fibrillation Recurrence after Catheter Ablation: A Meta-Analysis.

Authors:  Guangping Zhang; Yongquan Wu
Journal:  Cardiovasc Ther       Date:  2019-04-02       Impact factor: 3.023

2.  Galectin-3 and risk of atrial fibrillation: A systematic review and meta-analysis.

Authors:  Mengqi Gong; Angel Cheung; Qun-Shan Wang; Guangping Li; Christos A Goudis; George Bazoukis; Gregory Y H Lip; Adrian Baranchuk; Panagiotis Korantzopoulos; Konstantinos P Letsas; Gary Tse; Tong Liu
Journal:  J Clin Lab Anal       Date:  2020-01-09       Impact factor: 2.352

3.  Potential Target Genes in the Development of Atrial Fibrillation: A Comprehensive Bioinformatics Analysis.

Authors:  Liang Liu; Yun Yu; Long-Long Hu; Quan-Bin Dong; Feng Hu; Ling-Juan Zhu; Qian Liang; Ling-Ling Yu; Hui-Hui Bao; Xiao-Shu Cheng
Journal:  Med Sci Monit       Date:  2021-03-20

4.  Serum Beta-2 Microglobulin: A Possible Biomarker for Atrial Fibrillation.

Authors:  Bangying Zhang; Xinpei Chen; Xiaofeng Mu; Enzhao Liu; Tong Liu; Gang Xu; Qiankun Bao; Guangping Li
Journal:  Med Sci Monit       Date:  2021-11-22

Review 5.  Role of New Potential Biomarkers in the Risk of Thromboembolism in Atrial Fibrillation.

Authors:  Mario Piergiulio Pezzo; Antonella Tufano; Massimo Franchini
Journal:  J Clin Med       Date:  2022-02-09       Impact factor: 4.241

Review 6.  A Review of Biomarkers for Ischemic Stroke Evaluation in Patients With Non-valvular Atrial Fibrillation.

Authors:  Luxiang Shang; Ling Zhang; Yankai Guo; Huaxin Sun; Xiaoxue Zhang; Yakun Bo; Xianhui Zhou; Baopeng Tang
Journal:  Front Cardiovasc Med       Date:  2021-07-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.